BioCentury | Mar 11, 2013
Company News

Oncomatrix sales and marketing update

...to diagnose and prognose the invasiveness of tumors. The DMTXinvaScan uses a mAb developed by Oncomatrix...
...and its encoded protein, which are expressed in the stroma fibroblasts associated with invasive tumors. Oncomatrix S.L....
BioCentury | Dec 24, 2012
Company News

Oncomatrix, University of Stuttgart deal

...while Oncomatrix will generate corresponding immunotoxins and conduct in vivo testing and Phase I development. Oncomatrix...
...rights to IP resulting from the deal, while the university will be eligible for royalties. Oncomatrix S.L....
Items per page:
1 - 2 of 2
BioCentury | Mar 11, 2013
Company News

Oncomatrix sales and marketing update

...to diagnose and prognose the invasiveness of tumors. The DMTXinvaScan uses a mAb developed by Oncomatrix...
...and its encoded protein, which are expressed in the stroma fibroblasts associated with invasive tumors. Oncomatrix S.L....
BioCentury | Dec 24, 2012
Company News

Oncomatrix, University of Stuttgart deal

...while Oncomatrix will generate corresponding immunotoxins and conduct in vivo testing and Phase I development. Oncomatrix...
...rights to IP resulting from the deal, while the university will be eligible for royalties. Oncomatrix S.L....
Items per page:
1 - 2 of 2